Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH – Free Report) from a hold rating to a buy rating in a research report report published on Saturday,Wall Street Zen reports.
A number of other brokerages have also issued reports on ZBH. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a research report on Thursday, August 6th. Royal Bank Of Canada raised their price target on Zimmer Biomet from $110.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Sanford C. Bernstein lifted their price objective on shares of Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 4th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $113.79.
Get Our Latest Stock Analysis on ZBH
Zimmer Biomet Price Performance
Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet will post 8.56 earnings per share for the current year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet’s payout ratio is presently 24.30%.
Insider Buying and Selling
In other news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.28% of the company’s stock.
Institutional Trading of Zimmer Biomet
Several institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in Zimmer Biomet by 5.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,021,307 shares of the medical equipment provider’s stock valued at $90,723,000 after acquiring an additional 52,679 shares during the last quarter. Bellevue Group AG boosted its position in shares of Zimmer Biomet by 15.6% during the 3rd quarter. Bellevue Group AG now owns 146,474 shares of the medical equipment provider’s stock valued at $13,011,000 after purchasing an additional 19,767 shares in the last quarter. Empirical Finance LLC grew its stake in shares of Zimmer Biomet by 1.9% in the 3rd quarter. Empirical Finance LLC now owns 7,496 shares of the medical equipment provider’s stock worth $666,000 after purchasing an additional 139 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Zimmer Biomet in the 3rd quarter worth approximately $720,000. Finally, Empowered Funds LLC grew its stake in shares of Zimmer Biomet by 47.8% in the 3rd quarter. Empowered Funds LLC now owns 13,415 shares of the medical equipment provider’s stock worth $1,192,000 after purchasing an additional 4,336 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
Recommended Stories
- Five stocks we like better than Zimmer Biomet
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
